<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35646346</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1828-695X</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2022</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Multidisciplinary respiratory medicine</Title><ISOAbbreviation>Multidiscip Respir Med</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment.</ArticleTitle><Pagination><StartPage>825</StartPage><MedlinePgn>825</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">825</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4081/mrm.2022.825</ELocationID><Abstract><AbstractText>The relationship between SARS-CoV-2 quantitative viral load and risk of disease progression, morbidity such as long- COVID or mortality in immunosuppressed, remains largely undefined in COVID-19 patients. Critically ill immunosuppressed patients potentially benefit from remdesivir treatment because of the prolonged course of their infection. Four critically ill immunocompromised patients and the impact of remdesivir on viral dynamics in lower respiratory samples were studied. Bronchoalveolar lavage (BAL) samples were assessed to measure SARS-CoV-2 quantitative viral load using real-time PCR. Corresponding plasma levels of remdesivir and its metabolite GS-441524 were determined. Mean virus load of 39.74 x 10<sup>7</sup> geq/ml (&#xb1;33.25 x 10<sup>7</sup> geq/ml) on day 1 dropped significantly (p&lt;0.008) to 3.54 x 10<sup>6</sup> geq/ml (&#xb1;6.93 x 10<sup>6</sup> geq/ml) on day 3 and to 1.4 x 10<sup>5</sup> geq/ml (&#xb1;2.35 x 10<sup>5</sup> geq/ml) on day 5 of remdesivir treatment. Mean virus load dropped below &lt;1% between day 1 and 5 of remdesivir treatment. Parent prodrug remdesivir and also GS441524 metabolite levels of antiviral activity in our patients were far in excess of EC 50. Our data present that remdesivir treatment potentially reduces the SARS-CoV-2 viral load in immunosuppressed critically ill patients. However, the implication of viral load reduction on morbidity and mortality needs further investigation.</AbstractText><CopyrightInformation>&#xa9;Copyright: the Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lahmer</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erber</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Roland M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinner</LastName><ForeName>Christoph D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luppa</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Clinical Chemistry and Pathobiochemistry, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf6;rgel</LastName><ForeName>Fritz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IBMP - Institute for Biomedical and Pharmaceutical Research, N&#xfc;rnberg-Heroldsberg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinzig</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IBMP - Institute for Biomedical and Pharmaceutical Research, N&#xfc;rnberg-Heroldsberg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasch</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, University hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Multidiscip Respir Med</MedlineTA><NlmUniqueID>101477642</NlmUniqueID><ISSNLinking>1828-695X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">viral load</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>11</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35646346</ArticleId><ArticleId IdType="pmc">PMC9134301</ArticleId><ArticleId IdType="doi">10.4081/mrm.2022.825</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>D&#xf6;lken L, Stich A, Spinner CD. Remdesivir for early COVID- 19 treatment of high-risk individuals prior to or at early disease onset-lessons learned. Viruses 2021;13:963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8224666</ArticleId><ArticleId IdType="pubmed">34067381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukagoshi H, Shinoda D, Saito M, Okayama K, Sada M, Kimura H, et al. . Relationships between viral load and the clinical course of COVID-19. Viruses 2021;13:304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919281</ArticleId><ArticleId IdType="pubmed">33672005</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. . SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 2020;11:5493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603483</ArticleId><ArticleId IdType="pubmed">33127906</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;rgel F, Malin JJ, Hagmann H, Kinzig M, Bilal M, Eichenauer DA, et al. . Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. J Antimicrob Chemother 2021;76:825-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799013</ArticleId><ArticleId IdType="pubmed">33251541</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health 2021;9:123-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410793</ArticleId><ArticleId IdType="pubmed">32838064</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. . Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020;585:273-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486271</ArticleId><ArticleId IdType="pubmed">32516797</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg E, Ben Zvi H, Sheena L, Sofer S, Krause I, Sklan EH, et al. . A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. Clin Microbiol Infect 2021;27:917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7939997</ArticleId><ArticleId IdType="pubmed">33705849</ArticleId></ArticleIdList></Reference><Reference><Citation>Chokkalingam A, Li H, Asubonteng J, Mozaffari E, Wang JR, Bush C, et al. . Comparative effectiveness of remdesivir treatment in patients hospitalized with COVID-19. World Microbe Forum ASM 2021. Poster
2970. Available from: https://www.askgileadmedical.com/downloads/pdfs/conference-materials/covid-19/asm%202021/Chokkalingam%20AP.pdf</Citation></Reference><Reference><Citation>Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, et al. . Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun 2020;11:6385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736571</ArticleId><ArticleId IdType="pubmed">33318491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>